2,397 results on '"Engert, Andreas"'
Search Results
102. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation: A Planning Comparison Of Deep Inspiration Breath Hold Intensity Modulation Radiotherapy And Intensity Modulated Proton Therapy
103. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
104. Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
105. Erkrankungen des lymphatischen Systems
106. The Updated European Hematology Association Research Roadmap
107. Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis
108. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis
109. Erkrankungen des Blutes
110. Regelungen als Netzgüter: Eine Theorie der Rechtsvereinheitlichung im Vertragsrecht
111. Contracting over Private Benefits of Control: Comment
112. Quantification of Residual Tumor Cells in Monoclonal B-cell Lymphoma
113. The genetics of Hodgkin lymphoma: an overview and clinical implications
114. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
115. The GHSG Approach to Treating Hodgkin’s Lymphoma
116. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
117. Prognostic Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
118. Equality Between Efficiency and Distribution—A Law-and-Economics Reconceptualization of a Principle of Justice
119. Why manager liability fails at controlling systemic risk
120. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
121. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: When should they be considered and which questions remain open?
122. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci
123. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy
124. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial
125. BGH, 18. 9. 2006 — II ZR 137/05. Zur Problematik abgestimmten Verhaltens zwischen Großaktionären
126. Biology, Staging and Treatment of Hodgkin’s Disease
127. Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma
128. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
129. Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis
130. PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group
131. Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study
132. Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
133. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis
134. Norms, Rationality, and Communication: A Reputation Theory of Social Norms
135. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group
136. The Development of Ricin A-Chain Immunotoxins for Clinical Trials in Patients with Hodgkin’s Disease
137. Treatment of Early Unfavorable HL
138. Targeting CD30 in Patients with Hodgkin Lymphoma
139. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
140. Hodgkin lymphoma
141. Sixteenth Biannual Report of the Cochrane Haematological Malignancies Group: Focus on Non-Hodgkin’s Lymphoma
142. Die Entdeckung der Gesellschaft: Eric Posners "Law and Social Norms"
143. Antitumor Effects of Six Ricin A-Chain Immunotoxins of Potential Use in the Treatment of Hodgkin’S Disease
144. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
145. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
146. HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
147. Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer
148. Poster: HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
149. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
150. Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.